Equity Profile

STVN

Stevanato Group S.p.A.

Health CareLife Sciences Tools & Services$5.1B

May7Thu

Post-Earnings Recap

ReportedQ1-2026Pre-Market6:30 AM EDT

Stevanato Group Beats on EPS, Stock Down 5.1%

Metric	Actual	Expected	Surprise
EPS	$0.13	$0.12	+5.44%
Revenue	N/A	$269M	N/A

management commentary, guidance changes, and full analysis available with Pro.

Stevanato Group Beats on EPS, Stock Down 5.1%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$0.13	$0.12	+5.44%
Revenue	N/A	$269M	N/A

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based solely on numerical results.

What It Means

Stevanato Group reported better-than-expected earnings per share, but did not provide revenue figures. The stock reacted negatively, dropping 5.1%, which may indicate investor concerns despite the EPS beat. The lack of guidance and revenue information could have contributed to the stock's decline.

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a crucial indicator of the company's profitability and financial health, which investors closely monitor.

$0.12

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$269M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Stevanato Group S.p.A. is a healthcare company that specializes in life sciences tools and services, particularly focusing on the production of glass vials and other packaging solutions for the pharmaceutical industry. As a key player in the healthcare sector, the company is positioned to benefit from ongoing trends in drug development and increased demand for safe and effective drug delivery systems.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+4.93%

Avg Stock Reaction

+4.40%

Last Quarter Recap

In Q4 2025, Stevanato reported earnings of $0.20 per share, matching analyst expectations, and the stock rose by 18.81% the following day. The company has shown a consistent ability to meet or exceed earnings expectations in recent quarters.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Stevanato to report earnings of $0.12 per share and revenue of $269 million for Q1 2026, reflecting stable performance amid a challenging market. Investors will be keen to see if the company can maintain its growth trajectory.

Bull Case

If Stevanato exceeds earnings expectations and demonstrates strong revenue growth, it could signal robust demand for its products, potentially leading to a significant stock price increase.

Bear Case

Conversely, if the company misses earnings or revenue targets, it may raise concerns about its market position and future growth prospects, leading to a negative reaction in the stock.

Key Metrics to Watch

EPS

$0.12

Earnings per share is a crucial indicator of the company's profitability and financial health, which investors closely monitor.

Revenue

$269M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS exceed the consensus estimate of $0.12?

A beat on EPS would reinforce investor confidence in the company's profitability and growth potential.

What is the revenue outlook compared to the consensus of $269 million?

Revenue performance will be critical in assessing demand for Stevanato's products and overall market health.

Edge

What the Street Is Missing

Why consensus could be wrong

While consensus expects stable earnings, the market may be underestimating the potential for Stevanato to capitalize on increased demand for drug delivery systems, particularly in emerging markets.

Supporting Evidence

The company's recent performance has shown a consistent ability to exceed expectations, suggesting potential for continued growth.

Options pricing reflects a significant expected move, indicating that traders anticipate volatility that may not be fully captured by consensus estimates.

Key Risk

If revenue growth exceeds $269 million, it could challenge the current bearish sentiment and shift investor outlook positively.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Stevanato can sustain its growth amid competitive pressures and changing market dynamics.

Bull Confirmed If

Earnings exceeding $0.12 with revenue above $269 million would confirm the bull case.

Bear Confirmed If

Earnings below $0.11 or revenue falling short of $267 million would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±42.28%

Historical Avg

±8.7%

Pricing cheap

The options market is pricing in a significant move for Stevanato's stock, indicating that traders expect a high level of volatility around the earnings report.

Options are pricing ±7.0% while STVN has averaged ±8.7% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.8%

30d HV

37.6%

Calls (200)P/C Ratio: 0.14Puts (100)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Stevanato beats expectations, history suggests the stock could rise around 3.1% on the next trading day, confirming strong demand and operational efficiency.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance on future growth.

Miss

Should the company miss expectations, history indicates a potential decline of around 4.77%, raising concerns about its market position.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches and their expected impact on revenue.
2Any commentary on market demand trends for pharmaceutical packaging solutions.
3Insights into operational efficiencies and cost management strategies.
4Management's outlook on future growth in emerging markets.
5Responses to competitive pressures and how the company plans to address them.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

NCLHReported

Norwegian Cruise Line Holdings Ltd.

RecapView

May4

AXSMReported

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a crucial indicator of the company's profitability and financial health, which investors closely monitor.

$0.12

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$269M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+4.93%

Avg Stock Reaction

+4.40%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Stevanato exceeds earnings expectations and demonstrates strong revenue growth, it could signal robust demand for its products, potentially leading to a significant stock price increase.

Bear Case

Conversely, if the company misses earnings or revenue targets, it may raise concerns about its market position and future growth prospects, leading to a negative reaction in the stock.

Key Metrics to Watch

EPS

$0.12

Earnings per share is a crucial indicator of the company's profitability and financial health, which investors closely monitor.

Revenue

$269M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS exceed the consensus estimate of $0.12?

A beat on EPS would reinforce investor confidence in the company's profitability and growth potential.

What is the revenue outlook compared to the consensus of $269 million?

Revenue performance will be critical in assessing demand for Stevanato's products and overall market health.

Edge

What the Street Is Missing

Why consensus could be wrong

While consensus expects stable earnings, the market may be underestimating the potential for Stevanato to capitalize on increased demand for drug delivery systems, particularly in emerging markets.

Supporting Evidence

The company's recent performance has shown a consistent ability to exceed expectations, suggesting potential for continued growth.

Options pricing reflects a significant expected move, indicating that traders anticipate volatility that may not be fully captured by consensus estimates.

Key Risk

If revenue growth exceeds $269 million, it could challenge the current bearish sentiment and shift investor outlook positively.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Stevanato can sustain its growth amid competitive pressures and changing market dynamics.

Bull Confirmed If

Earnings exceeding $0.12 with revenue above $269 million would confirm the bull case.

Bear Confirmed If

Earnings below $0.11 or revenue falling short of $267 million would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±42.28%

Historical Avg

±8.7%

Pricing cheap

The options market is pricing in a significant move for Stevanato's stock, indicating that traders expect a high level of volatility around the earnings report.

Options are pricing ±7.0% while STVN has averaged ±8.7% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.8%

30d HV

37.6%

Calls (200)P/C Ratio: 0.14Puts (100)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Stevanato beats expectations, history suggests the stock could rise around 3.1% on the next trading day, confirming strong demand and operational efficiency.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance on future growth.

Miss

Should the company miss expectations, history indicates a potential decline of around 4.77%, raising concerns about its market position.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches and their expected impact on revenue.
2Any commentary on market demand trends for pharmaceutical packaging solutions.
3Insights into operational efficiencies and cost management strategies.
4Management's outlook on future growth in emerging markets.
5Responses to competitive pressures and how the company plans to address them.